MindWalk Stock Comparisons Highlight Analyst Upside

Four stock-comparison reports assess MindWalk against Mettler-Toledo, Fortrea and Ginkgo Bioworks across analyst ratings, valuation, risk, profitability and ownership. The reports generally cite MindWalk’s higher analyst-rated upside and lower share-price volatility than those peers, while noting its institutional ownership is low at 6.7%. Fortrea is described as having lower revenue but higher earnings than MindWalk and a lower price-to-earnings ratio; Mettler-Toledo leads MindWalk on 10 of 15 comparison measures, while MindWalk leads Fortrea on nine and Ginkgo on eight. MindWalk says it uses its HYFT Technology, LensAI and ReefIQ platforms to discover and develop biologics and AI-enabled drug discovery.